Insilico Medicine, a biotech company that uses artificial intelligence to discover and develop new drugs, is reporting two notable milestones.
According to thebambooworks.com, Insilico's revenue has climbed above $100 million, a jump the outlet attributes to the company's AI drug partnerships. In practice, that means Insilico is earning money by working with other drugmakers to speed up the hunt for promising new medicines using its software.
Separately, Endpoints News reports that Insilico and Bora Pharma have revealed plans to form an AI-driven manufacturing company. That signals an ambition to extend AI beyond the laboratory discovery stage and into how drugs are actually produced.
Taken together, the two developments point to a company trying to build an AI presence across more of the pharmaceutical pipeline — from finding drug candidates to making them. The revenue figure suggests that partners are willing to pay for AI-assisted drug work, while the manufacturing venture with Bora Pharma is an early step into a different, more industrial part of the business.
The sources here are headline-level, so the finer details — such as the size of the new manufacturing venture, its timeline, or how the two partners will split the work — are not specified in the material provided.
Why it matters: crossing $100 million in revenue while branching into AI-driven manufacturing is a sign that artificial intelligence in drug development is moving from experimental promise toward a paying, expanding business.